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In this study, we sought to elucidate the effects of treprostinil, a prostacyclin 
(PGI2) analog, on hemodynamics and vascular remodeling in a rat model of 
monocrotaline (MCT)-induced pulmonary hypertension.  First, male, Sprague-Dawley 
rats were randomized to one of four treatment groups; control, MCT only, MCT with 
treprostinil (TRE) treatment, and TRE only.  Next, rats received a one-time subcutaneous 
dose of MCT or saline and were administered either treprostinil or placebo for 28-days 
via an osmotic pump implanted subcutaneously.  Finally, 28-eight days post-pump 
implantation, we recorded right ventricular systolic pressure (RVSP) and right ventricular 
size.  Lung tissues were also collected and either paraffin embedded or snap frozen.  
MCT exposure caused significant increases in RVSP, right ventricular hypertrophy, 
medial wall thickening (MWT), and PPAR-γ protein expression.  Treprostinil did not 
decrease elevations of RVSP, right ventricular hypertrophy, or MWT, but it significantly 
lowered PPAR-γ protein expression.  In conclusion, we demonstrated that treprostinil 
therapy does not lessen increased RVSP, right ventricular hypertrophy and vascular 
remodeling associated with MCT-induced pulmonary hypertension.  Conversely, 
treprostinil treatment attenuated increased PPAR-γ protein levels in whole lung 
homogenates of MCT-exposed rats.  Although we have not yet established that PPAR-γ 
is an important therapeutic target for pulmonary hypertension, we speculate that further 
investigation of its role could reveal a mechanism in which PGI2 elicits its effects on the 
pulmonary vasculature. 
 
 
 
